View Post

Ipatasertib Survival Results Continue to Impress in TNBC

In Clinical Studies News by Barbara Jacoby

By: Jason M. Broderic From: Adding the oral AKT inhibitor ipatasertib to paclitaxel continued to demonstrate a clinically meaningful extension in overall survival (OS) in patients with locally advanced or metastatic triple-negative breast cancer (TNBC), according to the final analysis of the phase 2 LOTUS trial presented during the 2020 ESMO breast cancer virtual meeting.1 In the intention-to-treat (ITT) …